Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy

  • Technology appraisal guidance
  • TA1040
  • Published: 

History

Documents created during the development process.

Final draft guidance

Invitation to participate

Review proposal consultation